The results of the SURPASS trials demonstrate that tirzepatide yields clinically major improvements in glycemic Command and weight reduction in comparison with other GLP-1 receptor agonists (semaglutide and dulaglutide), insulin degludec, and insulin glargine.Skovronsky mentioned he hopes that retatrutide could in the future give the identical amo